Insider · CIK 0001535596
MarDee Haring-Layton
Files at DARE (Dare Bioscience, Inc.). First filing -, latest -.
In brief
MarDee Haring-Layton files SEC Form 4 as officer at DARE (Dare Bioscience, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; MarDee Haring-Layton has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 30, 2026 | DARE Dare Bioscience, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +49,000 | $0.00 | $0 | 49,000 | Feb 2, 2026 |
| Sep 4, 2025 | DARE Dare Bioscience, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +57,000 | $0.00 | $0 | 57,000 | Sep 4, 2025 |
| Jan 28, 2025 | DARE Dare Bioscience, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +38,000 | $0.00 | $0 | 38,000 | Jan 31, 2025 |
Questions about MarDee Haring-Layton
Answered from the filings on this page, as of the latest one.
Is MarDee Haring-Layton buying or selling?
MarDee Haring-Layton has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did MarDee Haring-Layton's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and MarDee Haring-Layton has 0.
Where does MarDee Haring-Layton file Form 4?
MarDee Haring-Layton has filed Form 4 at DARE (Dare Bioscience, Inc.) as Chief Accounting Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.